Medical Hypotheses
Volume 55, Issue 6 , Pages 491-493 , December 2000

Can the cognitive enhancing effects of Ginkgo biloba be explained by its pharmacology?

Received 10 November 1999 ,Accepted 16 February 2000.

References 

    REFERENCES
  1. Choppin P, Briley M. Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine induced amnesia in rats. Psychopharmacol. 1992;106:26–30
  2. Del Cerro S, Arai A, Lynch G. Inhibition of long-term potentiation by an antagonist of platelet activating factor receptors. Behav Neural Biol. 1990;54:213–217
  3. Dillon KA, Gross-Isseroff R, Israeli M, Biegon A. Autoradiographic analysis of serotonin 5-HT1Areceptor binding in the human brain postmortem: effects of age and alcohol. Brain Res. 1991;554:56–64
  4. Drachman DA, Leavitt J. Human memory and the cholinergic system. Arch Neurol. 1974;30:113–121
  5. Drieu K. Preparation et definition de l’extrait de Ginkgo biloba. Presse Med. 1986;15:1455–1457
  6. Francis PT, Palmer AM, Snape M, Wilcock G. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiat. 1999;66:137–147
  7. Franklin AH. Historical summary and bibliography. Virginia J Sci. 1959;10:131–176
  8. Frolich L, Riederer P. Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Drug Res. 1995;45:443–446
  9. Gajewski A, Hensch SA. Ginkgo biloba and memory for a maze. Psychological Reports. 1999;84:481–484
  10. Halliwell B, Gutteridge J. Oxygen radicals and the nervous system. Trends Neurosci. 1985;8:22–26
  11. Huguet F, Drieu K, Piriou A. Decreased cerebral 5-HT1Areceptors during aging: reversal by Ginkgo biloba extract (EGb 761). J Pharm Pharmacol. 1994;46:316–318
  12. Izumi J, Wahizuka M, Miura N, Hiraga Y, Ikeda Y. Hippocampal serotonin 5-HT1Areceptors enhances acetylcholine release in conscious rats. J Neurochem. 1994;62:1804–1808
  13. Jenner P. Oxidative damage in neurodegenerative disease. Lancet. 1994;344:796–799
  14. Koltai M, Hosford D, Guinot P, Esanu A, Braquet P. Platelet-activating factor (PAF): a review of its effects, antagonists and future clinical implications. Drugs. 1991;42:9–29
  15. Koyama T, Nakajima Y, Fugii T, Kawashima K. Enhancement of cortical and hippocampal cholinergic neurotransmission through 5-HT1Areceptor mediated pathways by BAY3702 in freely moving rats. Neurosci Lett. 1999;265:33–36
  16. Kristoflikova Z, Klaschka J. In vitro effect of Ginkgo biloba extract (Egb 761) on the activity of pre-synaptic cholinergic nerve terminals in rat hippocampus. Dement Geriatr Cogn Disord. 1997;8(1):43–48
  17. Lacomblez L, Warot D, Tarrade T, Puech AJ. Psychopharmacological effects of Ginkgo biloba extract (Egb 176) in healthy volunteers. Eur J Pharmacol. 1990;183:1460
  18. Markesbery WR. Oxidative stress hypothesis of Alzheimer’s disease. Free Radic Biol Med. 1997;23:134–147
  19. Maitra I, Marcocci L, Droy-Lefaix MT, Packer L. Peroxy radical scavenging activity of ginkgo biloba extract Egb761. Biochem Pharmacol. 1995;49:1649–1655
  20. Ni Y, Zhao B, Hou J, Xin W. Preventive effect of Ginkgo biloba on apoptosis in rat cerebellar neuronal cells induced by hydroxy radicals. Neurosci Lett. 1996;214:115–118
  21. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer’s disease. Arch Neurol. 1998;55:1409–1415
  22. Oyama Y, Fuchs PA, Katayama N, Noda K. Myricetin and queretin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca2+ loaded brain neurons. Brain Res. 1994;635:125–129
  23. Oyama Y, Chikahisa L, Ueha T, Kahemaru K, Noda K. Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Brain Res. 1996;712:349–352
  24. Rai GS, Shovlin C, Wesnes KA. A double blind, placebo controlled study of Ginkgo biloba extract (Tanakan) in elderly patients with mild to moderate memory impairment. Curr Med Res Opin. 1991;12:350–355
  25. Rigney U, Kimber S, Hindmarch I. The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. Phytother Res. 1999;13(5):408–415
  26. Sano M, Ernesto C, Klauber M. Rationale and design of a multicenter study of selegiline and α-tocopherol in the treatment of Alzheimer’s disease using novel clinical outcomes. Alzheimer Dis Assoc Disord. 1996;10:132–140
  27. Schneider LS. New therapeutic approaches to Alzheimer’s disease. J Clin Psychiat. 1996;57:30–36
  28. Soholm B. Clinical improvement of memory and other cognitive functions by Ginkgo biloba: Review of relevant literature. Ad Natural Ther. 1998;15(1):54–65
  29. Subhan Z, Hindmarch I. The psychopharmacological effects of Ginkgo biloba extract in normal healthy volunteers. Int J Clin Pharm Res. 1984;IV(2):89–93
  30. Taylor JE. Neuromediator binding to receptors in the rat brain. The effect of chronic administration of Ginkgo biloba extract. Presse Med. 1986;15:1491–1493
  31. Warbuton DM. Clinical psychopharmacology of Ginkgo biloba extract. Rokan (Ginkgo biloba). Recent results in pharmacology and clinic. Berlin, Springer-Verlag: EW Funlged,; 1986; p. 327–245
  32. White HL, Scates PW, Cooper BR. Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci. 1996;16:1315–1321
  33. Weingartner H. Models of memory dysfunction. Ann NY Acad Sci. 1985;444:359–369
  34. Wieraszko A, Li G, Kornecki E, Hogan MV, Ehrilich YH. Long-term potentiation in the hippocampus induced by platelet activating factor. Neuron. 1993;10:553–557
  35. Winter E. Effects of an extract of Ginkbo biloba on learning and memory in mice. Pharmacol Biochem Behav. 1991;38:109–114

PII: S0306-9877(00)91099-5

doi: 10.1054/mehy.2000.1099

Medical Hypotheses
Volume 55, Issue 6 , Pages 491-493 , December 2000

Article Tools